Skip to main content

HB 484 — Maryland

Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising

Introduced 2026 session House of Delegates

This page lists STATE bills only. Open States, our source for this data, tracks state legislatures -- it has no visibility into city councils, county commissions or school boards. We don't yet have a free, storable source for local measures; see the About page for why.

Summary

  • HB 484 is a bill in the Maryland House of Delegates, 2026 session, introduced January 23, 2026.
  • Sponsored by Ziegler, Feldmark, Terrasa, Addison, Charkoudian, Cullison, Ebersole, Guzzone, Hill, Moreno, and Watson.
  • Current status: introduced.
  • Most recent action (January 23, 2026): Hearing 2/12 at 1:00 p.m.
  • Subjects: Advertising, Commerce and Business, Corporations, Drugs, Electronic Communication, Exemptions.

Contact your legislator about this bill

Bill text & documents

Sponsors

Primary: Ziegler, Feldmark, Terrasa, Addison, Charkoudian, Cullison, Ebersole, Guzzone, Hill, Moreno, Watson

History

  1. Introduced, completed
  2. Passed House of Delegates, in progress
  3. Passed Senate, not reached yet
  4. Sent to Governor, not reached yet
  5. Signed into law, not reached yet
  1. House of Delegates First Reading Ways and Means
  2. House of Delegates Hearing 2/12 at 1:00 p.m. Latest

Source: Open States. Last checked November 18, 2026. How we keep this accurate ›